In recent years, the promising results of research into multiple sclerosis have raised all our hopes. Canada remains an undisputed leader in this field, and Quebec is undeniably contributing to the various advances being achieved. Proud of the exceptional contribution of the Quebec researchers, the Quebec Division is organizing the fourth Quebec Summit on MS. This initiative will bring together key actors who will pool their in-depth knowledge of multiple sclerosis and present the varied possibilities likely to open up in this field in the near future.
Dr. Philippe Beauchemin, a neurologist who specializes in multiple sclerosis, has been practising at Hôpital de l’Enfant-Jésus and the IRDPQ multiple sclerosis clinic in Quebec City since 2014. After completing his medical studies with a specialization in neurology at Université Laval, he completed a subspecialization in multiple sclerosis and a master’s degree in applied epidemiology at University of British Columbia.
Dr. Anthony Feinstein is a professor of psychiatry at University of Toronto who holds a master’s and a doctorate from University of London. For 26 years, he has been studying behavioural disorders in the context of MS, as well as directing a very busy clinic, where over 80% of the patients have this disease. Recently, he started a series of studies on the potential effects of cannabis on cognitive function and the results of brain imaging in people with MS. Dr. Feinstein is also a past chair of the MS Society of Canada’s Medical Advisory Committee.
After obtaining a degree in basic neurophysiology from McGill University in 1979, and a doctorate from the faculty of medicine at Université de Sherbrooke in 1983, Dr. Grand’Maison completed postdoctoral studies at Université de Sherbrooke and University of Western Ontario, in London, Ontario. Today, he is a professor of medicine at Université de Sherbrooke and a neurologist at Hôpital Charles-LeMoyne and is the founding director of the Neuro Rive-Sud multiple sclerosis clinic in the Montérégie region. He is participating in several clinical research projects on MS and is a valued partner of the MS Society as a lecturer and the author or coauthor of several publications.
Dr. Helen Tremlett, who has a doctorate from University of Cardiff, in the UK, has been interested in epidemiology and MS since the start of her education. Her research work focuses on various topics: the development of MS, the life expectancy of people with MS, the effects of MS on the development of the next generation, and links between the gut microbiome and MS are just a few of them. Dr. Tremlett’s research program is financed by operating grants from the Canadian Institutes of Health Research (CIHR), the MS Society of Canada, the MS Scientific Research Foundation and the National MS Society (the MS organization in the U.S.), among others.
Serge Marchand, Ph. D., is Vice-President, Scientific Affairs at Génome Québec. Prior to his appointment in January 2019, he served as the Scientific Director of the Fonds de recherche du Québec - Santé from 2017 to 2019. He has also been a Professor at the Faculty of Medicine and Health Sciences at the Université de Sherbrooke and a researcher at the Sherbrooke University Hospital Research Center, of which he has been the Scientific Director from 2008 to 2013. Serge Marchand has a doctorate in neuroscience from Université de Montréal and his research work focuses on the neurophysiological mechanisms responsible for the development and persistence of chronic pain. He is also the author of numerous scientific articles and has been a member of several national and international review committees.
After earning a degree in medicine from Université de Sherbrooke, Dr. Emmanuelle Lapointe completed her residency in neurology at the same institution and then did additional training on multiple sclerosis and neuromyelitis optica at University of British Columbia. She is now a neurologist and assistant professor at the Sherbrooke university hospital (CHUS), where she also serves as director of the multiple sclerosis clinic. Dr. Lapointe devotes most of her time to clinical practice although she is also active in clinical research.
Dr Prat is a staff neurologist at the CHUM (Montréal) and is Full Professor of Neurosciences (with Tenure) at Université de Montréal. Dr. Prat held the Donald Paty Research Chair of the Multiple Sclerosis Society of Canada and was a senior Scholar of the FRQ-S (2012-2016). He now holds the Senior Canada Research Chair in Multiple Sclerosis and was inducted at the College of researcher of the Royal Society of Canada in 2015. He currently acts as Deputy Director for Development at the CHUM Research Center, a research institution with over 120 investigators and 2000 employees.
The current research interests of the Prat lab include the immunological roles of the human blood-brain barrier (BBB), the mechanisms of monocytes and lymphocyte migration across the BBB and the physiological regulation of the Blood-Brain Barrier functions by glial cells.